340B Drug Pricing Program
Thirty-five state and regional hospital associations today urged the U.S. Court of Appeals for the District of Columbia Circuit to reverse a district court decision and grant a preliminary injunction to stop a nearly 30% Medicare payment reduction for many hospitals in the 340B Drug Pricing Program…
Amici curiae are 35 state and regional hospital associations that represent thousands of hospitals and health systems. Amici and their members are fully committed to improving the health of the communities they serve through the delivery of high quality, efficient, and accessible health care. The…
The U.S. health care system is facing a prescription drug spending crisis fueled by staggering increases in recent years in the price of drugs.
The lower court incorrectly dismissed as premature their lawsuit to prevent a nearly 30% Medicare payment reduction for many hospitals in the 340B Drug Pricing Program, AHA and other hospital groups told a federal appeals court in a brief filed yesterday.
Filed 02-15-2018
NO. 18-5004; THE AMERICAN HOSPITAL ASSOCIATION, et al., Plaintiffs-Appellants, v. ALEX M. AZAR II, in his official capacity, et al., Defendants-Appellees, On Appeal from a Final Judgment of the U.S. District Court for the District of Columbia, (Honorable Rudolph Contreras)
The American Hospital Association's comments to the Energy and Commerce Subcommittee on Oversight and Investigations for its hearing on "Examining the Impact of Health Care Consolidation."
AHA Special Bulletin: White House Releases FY 2019 Budget Request with Medicare, Medicaid Reductions
President Trump today submitted to Congress his budget request for fiscal year (FY) 2019.
A recent study published in the New England Journal of Medicine on the 340B program includes a number of methodological flaws that invalidate the findings, including one major flaw: how the authors ignored a significant data source in drawing their conclusions.
The AHA today said that a recent study published in the New England Journal of Medicine “fails to draw meaningful, valid conclusions” about the 340B Drug Pricing Program “due to constraints and flaws” in the methodology.
The 340B Drug Savings Program provides eligible providers, many of which are hospitals, with resources to maintain vital services in their communities and to provide additional services to their patients. A recent study published in the New England Journal of Medicine alleges that the 340B program…